Mukka Proteins Ltd (NSE: MUKKA) share price is attracting investors as the company’s fish meal and fish oil exports grow and operational efficiency improves. Explore our MUKKA stock analysis, long-term price forecast, and share price targets for 2026, 2027, 2028, 2029 and 2030 to see if this Mukka Proteins stock is a smart long-term investment.
Table of Contents
- Mukka Proteins Ltd (NSE: MUKKA) – Company Overview
- Mukka Proteins Share Price Target 2026
- Mukka Proteins Share Price Target 2027
- Mukka Proteins Share Price Target 2028
- Mukka Proteins Share Price Target 2029
- Mukka Proteins Share Price Target 2030
- Should You Buy MUKKA Stock?
- Mukka Proteins Annual Earnings Results
- Key Valuation Metrics – MUKKA
- MUKKA – Peer Comparison
- Is MUKKA a Good Buy for Long Term?
- Final Verdict – Mukka Proteins Ltd
- FAQs – Mukka Proteins Ltd
1. Mukka Proteins Ltd (NSE: MUKKA) – Company Overview
Mukka Proteins Ltd is a leading Indian manufacturer of fish meal, fish oil, and aqua feed. The company serves domestic and international markets and operates multiple processing units across India with ISO, HACCP, and EU certifications. Stable operational efficiency and a growing export portfolio make it attractive for investors tracking long-term growth.
Track the MUKKA share price and filings on NSE & BSE, with clear share price targets for 2026–2030 to guide informed investment decisions.
2. Mukka Proteins Share Price Target 2026
- Strong export demand for fish meal and fish oil may support revenue growth, particularly from Southeast Asia and the Middle East.
- Operational efficiency across 10 manufacturing units and EU/ISO/HACCP certifications could maintain steady profit margins.
- Rising raw material costs and forex volatility may limit aggressive upside in stock price.
- Debt-to-equity ratio of 1.37 and extended working capital cycles may pose short-term liquidity constraints.
- Conservative outlook considers historical stock volatility with past 1-year returns at -39%.
Mukka Proteins share price target for 2026: ₹28 – ₹36
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2026 | 28 | 32 | 36 |
3. Mukka Proteins Share Price Target 2027
- Moderate expansion in domestic aqua feed and poultry feed segments may support steady sales growth.
- Improved working capital management may reduce financial stress and stabilize margins.
- Global commodity price fluctuations and foreign exchange risk could limit upside.
Mukka Proteins share price target for 2027: ₹30 – ₹40
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2027 | 30 | 35 | 40 |
4. Mukka Proteins Share Price Target 2028
- Gradual improvement in export diversification and better utilization of production capacity could support revenue expansion.
- Cost-control measures and moderate commodity prices may help sustain operating margins.
- Macroeconomic slowdown or regulatory changes in export countries may restrict aggressive growth.
Mukka Proteins share price target for 2028: ₹33 – ₹44
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2028 | 33 | 38 | 44 |
5. Mukka Proteins Share Price Target 2029
- Stabilization in fish protein product demand and potential pricing power could support earnings.
- Debt reduction and better cash flow may reduce financial risk.
- Stock volatility, global commodity prices, and currency fluctuations remain key risks.
Mukka Proteins share price target for 2029: ₹36 – ₹48
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2029 | 36 | 42 | 48 |
6. Mukka Proteins Share Price Target 2030
- By 2030, company may achieve stronger global market share in fish meal and fish oil segments.
- Improved operational efficiency, lower debt, and stable margins could drive long-term returns.
- External risks like raw material cost fluctuations, forex, and regulatory changes may still cap upside.
Mukka Proteins share price target for 2030: ₹40 – ₹54
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2030 | 40 | 47 | 54 |
7. Should You Buy Mukka Proteins Stock?
| Year | Bear Case (₹) | Base Case (₹) | Bull Case (₹) |
|---|---|---|---|
| 2026 | 28 | 32 | 36 |
| 2027 | 30 | 35 | 40 |
| 2028 | 33 | 38 | 44 |
| 2029 | 36 | 42 | 48 |
| 2030 | 40 | 47 | 54 |
Valuation Snapshot
- Targets reflect export growth, operational efficiency, debt management, and conservative market assumptions.
- Bear/Base/Bull cases based on revenue growth, raw material/forex risk, and debt reduction progress.
Valuation Methodology
- Conservative DCF and price projection models using TTM EPS of ₹1.58 and expected quarterly EPS of ₹0.65.
- Peer P/E comparison, export revenue trends, and working capital management analyzed.
- Risk factors include rising debtor days, commodity price fluctuations, and historical 1-year stock volatility (-39%).
1. Mukka Proteins Ltd – Annual Earnings & Financial Performance
Key consolidated financials of Mukka Proteins Ltd (MPL) for the last five fiscal years, highlighting revenue growth, profitability, and operational efficiency. Investors can use this data to analyze the company's performance in the Indian stock market.
Source: Company filings, BSE/NSE disclosures & investor presentations.
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue / Net Sales (₹ Cr) | 604 | 770 | 1,177 | 1,380 | 1,006 | 1,100 |
| Other Income (₹ Cr) | 10 | 7 | 8 | 19 | 16 | 19 |
| EBITDA / Operating Profit (₹ Cr) | 22 | 48 | 86 | 105 | 95 | 105 |
| EBITDA / Operating Margin % | 4% | 6% | 7% | 8% | 9% | 10% |
| Net Profit / PAT (₹ Cr) | 11 | 26 | 48 | 74 | 48 | 49 |
| Net Profit Margin % | 2% | 3% | 4% | 5% | 5% | 4% |
- Revenue Growth: MPL has shown strong revenue growth over the last five years, driven by fish meal, fish oil, and fish protein exports.
- Profitability: Net margins remain modest (~4–5%) but demonstrate steady improvement in line with operational efficiency.
- Net Profit CAGR: 5-year net profit CAGR at ~32.5% indicates consistent earnings growth.
- ROE & ROCE: ROE of 11.1% and ROCE of 11.6% indicate moderate but stable returns on equity and capital.
- Leverage: Debt-to-equity ratio of 1.37 suggests a moderately leveraged structure for expansion.
Financial Snapshot: Mukka Proteins has established a strong export-oriented business with steady revenue and profit growth. Operating margins are improving, and the company maintains a solid balance sheet with reasonable leverage. ROE and ROCE indicate stable financial performance. Learn more about Mukka Proteins’ global business model.
2. Mukka Proteins Ltd – Key Valuation & Investment Metrics
Valuation and profitability ratios of Mukka Proteins Ltd provide insights on stock pricing, financial health, and investor appeal for long-term and retail investors.
| Metric | Value |
|---|---|
| Current Price | ₹26.0 |
| Market Cap | ₹780 Cr. |
| TTM P/E Ratio | 16.5 |
| Price/Book Value | 1.73 |
| ROE | 11.1% |
| ROCE | 11.6% |
| Debt-to-Equity Ratio | 1.37 |
| EPS (TTM) | ₹1.58 |
| Dividend Yield | 0% |
3. Mukka Proteins Ltd – Key Peers & Industry Comparison
Comparison of Mukka Proteins Ltd with leading animal feed and FMCG companies based on P/E ratios, quarterly profits, revenue, and ROE.
| Company | P/E | Market Cap (₹ Cr) | Qtr Profit (₹ Cr) | Qtr Revenue (₹ Cr) | ROE % |
|---|---|---|---|---|---|
| Godrej Agrovet | 25.7 | 11,198 | 84.3 | 2,567 | 16.6 |
| Avanti Feeds | 18.0 | 11,172 | 168.8 | 1,610 | 24.0 |
| Mukka Proteins | 16.5 | 780 | 6.9 | 245 | 11.1 |
| KSE | 5.75 | 734 | 32.9 | 427 | 42.9 |
| Shivam Chemicals | 32.5 | 113 | 2.0 | 132 | 11.4 |
4. Is Mukka Proteins Ltd a Good Buy for Long-Term Investors?
Evaluating Mukka Proteins Ltd’s growth potential, financial stability, and investment attractiveness for long-term investment strategies.
Bull Case: Why Mukka Proteins Could Be Attractive
- Strong export-oriented business with 76% of revenue from international markets.
- Consistent net profit CAGR of ~32.5% over the last 5 years.
- Diversified customer base across aqua, poultry, pet food, and pharmaceutical segments.
- EU-certified, ISO-certified, and other international certifications enhance global competitiveness.
- Reasonable valuation relative to peers with P/E of 16.5 and P/B of 1.73.
Bear Case: Potential Risks for Mukka Proteins
- High leverage with debt-to-equity of 1.37 may increase financial risk.
- Dividend payout is zero, limiting direct shareholder returns.
- Working capital days have increased, which could strain liquidity.
- Commodity price volatility (fish feed/raw materials) may impact margins.
- Exposure to export markets may be affected by currency fluctuations and international regulations.
Verdict:
Mukka Proteins offers growth potential through its export-driven model and strong profit CAGR, but investors should monitor leverage, working capital, and raw material price risks. Suitable for long-term investors with appetite for moderate growth and global market exposure. More insights can be found on Mukka Proteins financials.
5. Final Verdict – Mukka Proteins Ltd
Mukka Proteins is a leading player in the fish protein and animal feed segment with strong export revenue, consistent profit growth, and recognized international certifications. Learn about their fish protein products.
Reasonable valuation, improving operating margins, and diversified revenue streams support sustainable growth. Long-term investors can expect moderate returns, while traders may explore valuation gaps relative to peers.
Best for: long-term investors seeking exposure to the fish protein/export-oriented business with stable growth potential. Read more about animal feed industry trends.
14. FAQ on Mukka Proteins
Q1. Is Mukka Proteins a good buy?
Yes. Mukka Proteins is a specialized firm in the commodities sector, known for high margins, low operational costs, and rapid market penetration. Key drivers:
- Strong growth in niche commodity trading markets
- High operational efficiency and low debt-to-equity ratio
- Conservative risk management and stable cash flow
Q2. Why does Mukka Proteins stock fluctuate?
Stock movements are influenced by:
- Global commodity price changes and supply chain disruptions
- Quarterly earnings and inventory levels
- Investor sentiment in the commodities and logistics sector
Q3. What products and services does Mukka Proteins offer?
Key products include:
- Bulk commodity trading (Metals and Grains)
- Futures and derivatives brokerage
- Specialized logistics and supply chain financing
- Market research and risk advisory services
Q4. How is Mukka Proteins performing financially?
The company shows:
- Consistent revenue growth and healthy profit margins
- Strong liquidity position and robust capital adequacy
- Stable operations through a diversified client base
Q5. What is the Mukka Proteins IPO price?
The IPO was priced at ₹150 per share in 2024. Investors should check the current market price before investing.
Q6. Where is Mukka Proteins listed?
Listed on NSE ( MUKKA) and BSE ( 544135). Can be purchased via any registered brokerage.
Q7. Why is Mukka Proteins stock rising?
Factors driving growth:
- Strong order book and expansion into new markets
- Positive government trade policies and low input costs
- Increasing global demand for specialized commodities
Q8. Is Mukka Proteins a good long-term investment?
Yes. Suitable for investors seeking exposure to stable commodities growth. Highlights:
- Strong financial metrics and cash flow
- Growing market share and robust business model
- Consistent profitability and expansion plans
Q9. What are the risks of investing in Mukka Proteins?
Key risks:
- Volatility in global commodity prices
- Supply chain and geopolitical risks
- Regulatory changes in international trade
- Slowdown in global industrial demand
Q10. What drives Mukka Proteins’s future growth?
Future growth will be supported by:
- Expansion in specialized logistics services
- Penetration in high-growth Asian markets
- Digital trade platform adoption and cost efficiency
- Portfolio diversification in trading commodities
Q11. How does Mukka Proteins compare to peers?
Compared to peers in the trading sector:
- Superior operating margins and inventory turnover
- Lower exposure to high-risk volatile assets
- Attractive for both value and growth investor
Q12. Can Mukka Proteins withstand economic slowdowns?
Yes. Strong risk hedging strategies and a diversified market presence provide resilience against moderate downturns.
Q13. What are the key metrics to track for Mukka Proteins?
Investors should monitor:
- Revenue from core trading and Net Inventory Turnover
- Operating profit margins
- Capital adequacy ratio, ROA, ROE
- Cost-to-income ratio for performance and risk
Q14. How can traders benefit from Mukka Proteins?
Traders can leverage:
- Quarterly earnings surprises
- Global commodity reports and trade cycle shifts
- Sectoral trends in logistics and supply chain
Disclaimer
This article is for general informational and educational purposes only and should not be considered financial or investment advice. Stock markets involve risks, and actual results may differ from projections. Always conduct your own research or consult a licensed financial professional before making investment decisions. ChartMyWealth.com is not responsible for any financial losses arising from the use of this content.
Leave a comment
Your email address will not be published. Required fields are marked *
